53.32M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.

Similar securities

Based on sector and market capitalization

Report issue